Latham & Watkins Advises the Underwriters in Sigilon Therapeutics’ Upsized Initial Public Offering

Sigilon Therapeutics, Inc., a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, has announced its upsized initial public offering of 7,000,000 shares of its common stock at an initial public offering price of US$18.00 per share. All of the shares are offered by Sigilon. Sigilon’s common stock began trading on the Nasdaq Global Market on December 4, 2020 under the symbol “SGTX.” 

Latham & Watkins LLP represented the underwriters in the offering with a life sciences capital markets team led by partners Peter Handrinos and Wesley Holmes, with associates Adam Johnson, Emily Henderson and Laura Harper.